QP's current programs are focussed on heart failure (HF) and subarachnoid hemorrhage (SAH). The lead clinical program, LYRIC-HF, is repositioning the drug lumacaftor to accelerate development of its first treatment targeting cognitive impairment in heart failure patients. Follow-on programs GENESiS-HF and GENESiS-SAH expand on the same cerebral mechanism approach with proprietary small molecule development. RESiST-HF differentiates QP's pipeline with a novel biologic approach to reduce cardiac injury after heart failure.